Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 172c; offers guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $244.96 -0.36%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $6.34, $1.72 better than the analyst estimate of $4.62. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $981.08 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2026 revenue of $4.25-4.5 billion, versus the consensus of $4.453 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Full Circle Lithium closes $5.14M private placement
- Phillips 66, Marathon Merger Talks Collapsed - Semafor
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
